0001104659-24-131554 Sample Contracts
FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 26th, 2024 • Quoin Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 20, 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Quoin Pharmaceuticals Ltd.Placement Agent Agreement • December 26th, 2024 • Quoin Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the "Agreement") between Maxim Group LLC, as the lead placement agent ("Maxim") (Maxim is also referred to herein as the "Placement Agent"), and Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the "Company"), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a "reasonable best efforts" basis, in connection with the proposed placement (the "Placement") of up to $6,800,000.00 of registered securities of the Company, consisting of: (i) ordinary shares, no par value (the "Ordinary Shares") represented by American Depositary Shares (the "ADSs"), with each ADS representing one Ordinary Share, (ii) pre-funded warrants to purchase Ordinary Shares represented by ADSs (the "Pre-Funded Warrants"), and (iii) Series F Warrants to purchase ADSs and Series G Warrants to purchase ADSs (the "Ordinary Warrants" and collectively with the Pre-Funded Warrants, the "
FORM OF AMENDMENT TO WarrantS to purchase ordinary shares represented by american depositary sharesWarrant Amendment • December 26th, 2024 • Quoin Pharmaceuticals, Ltd. • Pharmaceutical preparations
This AMENDMENT TO WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of December 20, 2024, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [·] (the “Holder”).